NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1052 coverThe Future of Hormone Therapy: What Basic Science and Clinical Studies Teach Us Volume 1052 published June 2005
Ann. N.Y. Acad. Sci. 1052: 201–209 (2005). doi: 10.1196/annals.1347.020
Copyright © 2005 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by WEBBER, K. M.
Articles by SMITH, M. A.
Search for Related Content
PubMed
PubMed Citation
Articles by WEBBER, K. M.
Articles by SMITH, M. A.
Estrogen Bows to a New Master: The Role of Gonadotropins in Alzheimer Pathogenesis

KATE M. WEBBERa, GEMMA CASADESUSa, MICHAEL W. MARLATTa, GEORGE PERRYa, CLIVE R. HAMLINa, CRAIG S. ATWOODb, RICHARD L. BOWENc AND MARK A. SMITHa

aInstitute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA
bSchool of Medicine, University of Wisconsin, and William S. Middleton Memorial Veterans Administration, Madison, Wisconsin 53706, USA
cVoyager Pharmaceutical Corporation, Raleigh, North Carolina 27615, USA

Address for correspondence: Mark A. Smith, Ph.D., Institute of Pathology, Case Western Reserve University, 2085 Adelbert Rd., Cleveland, OH 44106. Voice: 216-368-3670; fax: 216-368-8964. mark.smith{at}case.edu

Epidemiological data showing a predisposition of women to develop Alzheimer disease (AD) led many researchers to investigate the role of sex steroids, namely estrogen, in disease pathogenesis. Although there is circumstantial support for the role of estrogen, the unexpected results of the Women's Health Initiative (WHI) Memory Study, which reported an increase in the risk for probable dementia and impaired cognitive performance in postmenopausal women treated with a combination of estrogen and progestin, have raised serious questions regarding the protective effects of estrogen. Although explanations for these surprising results vary greatly, the WHI Memory Study cannot be correctly interpreted without a complete investigation of the effects of the other hormones of the hypothalamic-pituitary-gonadal (HPG) axis on the aging brain. Certain hormones of the HPG axis, namely, the gonadotropins (luteinizing hormone and follicle-stimulating hormone), are not only involved in regulating reproductive function via a complex feedback loop but are also known to cross the blood-brain barrier. We propose that the increase in gonadotropin concentrations, and not the decrease in steroid hormone (e.g., estrogen) production following menopause/andropause, is a potentially primary causative factor for the development of AD. In this review, we examine how the gonadotropins may play a central and determining role in modulating the susceptibility to, and progression of, AD. On this basis, we suggest that the results of the WHI Memory Study are not only predictable but also avoidable by therapeutically targeting the gonadotropins instead of the sex steroids.

Key Words: Alzheimer disease • andropause • estrogen • gonadotropins • luprolide acetate • luteinizing hormone • menopause




This article has been cited by other articles:


Home page
Clin Med ResHome page
K. M. Webber, G. Perry, M. A. Smith, and G. Casadesus
The Contribution of Luteinizing Hormone to Alzheimer Disease Pathogenesis
Clin. Med. Res., October 1, 2007; 5(3): 177 - 183.
[Abstract] [Full Text] [PDF]



footerLeft footerRight